A clinical-stage drug development company focussed on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus. Hear CMO Dr Mitchell Glass discuss Invion's programs.

Invion has two phase II drug candidates: INV102 (nadolol) – a beta blocker being repurposed to treat inflammatory lung conditions; and INV103 (ala-Cpn10) – a modified human protein targeted treat inflammation caused by autoimmune disease. Read more in the company’s latest corporate presentation